ArticleJournal of hazardous materials2021
Increased survivability of coronavirus and H1N1 influenza virus under electrostatic aerosol-to-hydrosol sampling.
Article in Journal of hazardous materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Development of a Platform forAerosol science and technology : the journal of the American Association for Aerosol Research · 2026Article
- PEG-SeNPs as therapeutic agents inhibiting apoptosis and inflammation of cells infected with H1N1 influenza A virus.Scientific reports · 2024Article
- Laboratory studies on the infectivity of human respiratory viruses: Experimental conditions, detections, and resistance to the atmospheric environment.Fundamental research · 2024Review
- Research advances in microfluidic collection and detection of virus, bacterial, and fungal bioaerosols.Mikrochimica acta · 2024Review
- Mechanisms, Techniques and Devices of Airborne Virus Detection: A Review.International journal of environmental research and public health · 2023Review
- Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine.Frontiers in immunology · 2023Article
- Direct capture and smartphone quantification of airborne SARS-CoV-2 on a paper microfluidic chip.Biosensors & bioelectronics · 2022Article
- Article
- Biosensor detection of airborne respiratory viruses such as SARS-CoV-2.SLAS technology · 2022Review
- Recent advancements in the measurement of pathogenic airborne viruses.Journal of hazardous materials · 2021Review
- Challenges and Perspectives for Biosensing of Bioaerosol Containing Pathogenic Microorganisms.Micromachines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Airborne virus susceptibility is an underlying cause of severe respiratory diseases, raising pandemic alerts worldwide. Following the first reports of the novel severe acute respiratory syndrome coronavirus-2 in 2019 and its rapid spread worldwide and the outbreak of a new highly variable strain of influenza A virus (H1N1) in 2009, developing quick, accurate monitoring and diagnostic approaches for emerging infections is considered critical. Efficient air sampling of coronaviruses and the H1N1 virus allows swift, real-time identification, triggering early adjuvant interventions. Electrostatic precipitation is an efficient method for sampling bio-aerosols as hydrosols; however, sampling conditions critically impact this method. Corona discharge ionizes surrounding air, generating reactive oxygen species (ROS), which may impair virus structural components, leading to RNA and/or protein damage and preventing virus detection. Herein, ascorbic acid (AA) dissolved in phosphate-buffered saline (PBS) was used as the sampling solution of an electrostatic sampler to counteract virus particle impairment, increasing virus survivability throughout sampling. The findings of this study indicate that the use of PBS+AA is effective in reducing the ROS damage of viral RNA by 95%, viral protein by 45% and virus yield by 60%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.